SG11201912774RA - Anti-bcma heavy chain-only antibodies - Google Patents
Anti-bcma heavy chain-only antibodiesInfo
- Publication number
- SG11201912774RA SG11201912774RA SG11201912774RA SG11201912774RA SG11201912774RA SG 11201912774R A SG11201912774R A SG 11201912774RA SG 11201912774R A SG11201912774R A SG 11201912774RA SG 11201912774R A SG11201912774R A SG 11201912774RA SG 11201912774R A SG11201912774R A SG 11201912774RA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- heavy chain
- bcma heavy
- bcma
- chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522355P | 2017-06-20 | 2017-06-20 | |
| PCT/US2018/038549 WO2018237037A2 (en) | 2017-06-20 | 2018-06-20 | Anti-bcma heavy chain-only antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201912774RA true SG11201912774RA (en) | 2020-01-30 |
Family
ID=62875339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201912774RA SG11201912774RA (en) | 2017-06-20 | 2018-06-20 | Anti-bcma heavy chain-only antibodies |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210147564A1 (en) |
| EP (1) | EP3642237A2 (en) |
| JP (2) | JP7303126B2 (en) |
| KR (1) | KR20200018498A (en) |
| CN (2) | CN110891971B (en) |
| AU (1) | AU2018289515A1 (en) |
| BR (1) | BR112019026907A2 (en) |
| CA (1) | CA3067584A1 (en) |
| IL (1) | IL271194A (en) |
| SG (1) | SG11201912774RA (en) |
| WO (1) | WO2018237037A2 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7432363B2 (en) | 2016-06-21 | 2024-02-16 | テネオバイオ， インコーポレイテッド | CD3 binding antibody |
| UA126384C2 (en) | 2016-09-14 | 2022-09-28 | Тенеобіо, Інк. | Cd3 binding antibodies |
| US11434299B2 (en) | 2016-12-21 | 2022-09-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| JP7288405B2 (en) * | 2017-06-30 | 2023-06-07 | アメリカ合衆国 | Anti-B cell maturation antigen chimeric antigen receptor with human domain |
| PE20201171A1 (en) | 2017-12-22 | 2020-10-28 | Teneobio Inc | HEAVY CHAIN ANTIBODIES JOINING CD22 |
| PE20210320A1 (en) | 2018-06-01 | 2021-02-16 | Novartis Ag | BINDING MOLECULES AGAINST BCMA AND THE USES OF THEM |
| WO2020018820A1 (en) | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF |
| AU2020291938A1 (en) | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
| IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| WO2021222578A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| CR20220656A (en) * | 2020-06-30 | 2023-03-01 | Teneobio Inc | Multi-specific antibodies binding to bcma |
| US20230265181A1 (en) * | 2020-08-20 | 2023-08-24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Single variable domain and antigen binding molecule binding bcma |
| AU2022256638A1 (en) * | 2021-04-15 | 2023-11-09 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Multi-specific antibody targeting bcma |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| LU91067I2 (en) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab and its variants and immunochemical derivatives including immotoxins |
| AU6232899A (en) | 1999-10-06 | 2001-05-10 | Campina Melkunie B.V. | Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa |
| UA74798C2 (en) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors |
| EP1362061A2 (en) | 2001-02-20 | 2003-11-19 | ZymoGenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| SG188080A1 (en) | 2004-07-22 | 2013-03-28 | Univ Erasmus Medical Ct | Binding molecules |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| WO2007117600A2 (en) | 2006-04-07 | 2007-10-18 | Macrogenics, Inc. | Combination therapy for treating autoimmune diseases |
| AU2008259939B2 (en) | 2007-06-01 | 2014-03-13 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| AU2009239437B2 (en) | 2008-04-25 | 2014-11-13 | University Of Washington | Levels of BCMA protein expression on B cells and use in diagnostic methods |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| HUE025778T2 (en) * | 2008-07-17 | 2016-05-30 | Novartis Ag | Compositions and methods of use for therapeutic antibodies |
| DK2406284T5 (en) | 2009-03-10 | 2017-06-12 | Biogen Ma Inc | ANTI-BCMA ANTIBODIES |
| GB0905023D0 (en) * | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2012066058A1 (en) | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
| WO2012122512A1 (en) * | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
| TW201425336A (en) * | 2012-12-07 | 2014-07-01 | Amgen Inc | BCMA antigen binding proteins |
| CN111848796A (en) | 2013-02-05 | 2020-10-30 | 英格玛布有限责任公司 | Method for selecting antibodies against BCMA |
| EP2762497A1 (en) * | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| AU2014409276A1 (en) * | 2014-10-22 | 2017-04-06 | Crescendo Biologics Limited | Transgenic mice |
| GB201500461D0 (en) * | 2015-01-12 | 2015-02-25 | Cresendo Biolog Ltd | Therapeutic molecules |
| CN105384825B (en) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | A kind of bispecific chimeric antigen receptor and its application based on single domain antibody |
| WO2017031104A1 (en) * | 2015-08-17 | 2017-02-23 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
| JP7432363B2 (en) * | 2016-06-21 | 2024-02-16 | テネオバイオ， インコーポレイテッド | CD3 binding antibody |
| US20190225671A1 (en) * | 2016-08-24 | 2019-07-25 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
| UA126384C2 (en) * | 2016-09-14 | 2022-09-28 | Тенеобіо, Інк. | Cd3 binding antibodies |
| US11434299B2 (en) | 2016-12-21 | 2022-09-06 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
-
2018
- 2018-06-20 WO PCT/US2018/038549 patent/WO2018237037A2/en unknown
- 2018-06-20 CN CN201880040496.1A patent/CN110891971B/en active Active
- 2018-06-20 BR BR112019026907-0A patent/BR112019026907A2/en unknown
- 2018-06-20 CN CN202410016901.3A patent/CN117866097A/en active Pending
- 2018-06-20 KR KR1020197038377A patent/KR20200018498A/en not_active Application Discontinuation
- 2018-06-20 CA CA3067584A patent/CA3067584A1/en active Pending
- 2018-06-20 SG SG11201912774RA patent/SG11201912774RA/en unknown
- 2018-06-20 AU AU2018289515A patent/AU2018289515A1/en active Pending
- 2018-06-20 JP JP2019570103A patent/JP7303126B2/en active Active
- 2018-06-20 EP EP18740041.1A patent/EP3642237A2/en active Pending
- 2018-06-20 US US16/622,881 patent/US20210147564A1/en active Pending
-
2019
- 2019-12-05 IL IL271194A patent/IL271194A/en unknown
-
2022
- 2022-09-06 JP JP2022141179A patent/JP2022174169A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018237037A2 (en) | 2018-12-27 |
| CN117866097A (en) | 2024-04-12 |
| EP3642237A2 (en) | 2020-04-29 |
| AU2018289515A2 (en) | 2020-02-20 |
| CN110891971B (en) | 2024-01-12 |
| JP2022174169A (en) | 2022-11-22 |
| IL271194A (en) | 2020-01-30 |
| CN110891971A (en) | 2020-03-17 |
| RU2020100891A (en) | 2021-07-20 |
| RU2020100891A3 (en) | 2021-07-20 |
| JP2020524506A (en) | 2020-08-20 |
| BR112019026907A2 (en) | 2020-06-30 |
| CA3067584A1 (en) | 2018-12-27 |
| WO2018237037A3 (en) | 2019-02-07 |
| AU2018289515A1 (en) | 2020-02-06 |
| JP7303126B2 (en) | 2023-07-04 |
| KR20200018498A (en) | 2020-02-19 |
| US20210147564A1 (en) | 2021-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267485A (en) | Anti-bcma heavy chain-only antibodies | |
| IL271194A (en) | Anti-bcma heavy chain-only antibodies | |
| IL268517A (en) | Anti-tigit antibodies | |
| ZA201905966B (en) | Anti-lag3 antibodies | |
| IL272227A (en) | Anti-tigit antibodies | |
| GB201709808D0 (en) | Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| SG10201914130VA (en) | GARP-TGF-β ANTIBODIES | |
| ZA202002141B (en) | Anti-transthyretin antibodies | |
| GB201610044D0 (en) | Antibodies | |
| GB201603291D0 (en) | Antibodies | |
| GB201720970D0 (en) | Antibodies | |
| ZA202103456B (en) | Anti-alpha-synuclein antibodies | |
| IL271067A (en) | Anti-trkb antibodies | |
| GB201616699D0 (en) | Antibodies | |
| GB201612337D0 (en) | Ant-il-22r antibodies | |
| GB201711785D0 (en) | Antibodies | |
| GB201717006D0 (en) | Anti-OPG antibodies | |
| GB201709818D0 (en) | Antibodies | |
| GB201703071D0 (en) | Antibodies | |
| GB201701416D0 (en) | Anti-OPG antibodies | |
| GB201622197D0 (en) | Antibodies | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies |